HEAD AND NECK SQUAMOUS CELL CARCINOMA

This study is testing whether giving two immunotherapy drugs before surgery is safe and can help shrink tumors in people with head and neck cancer. The drugs, nivolumab and BMS-986253, aim to boost the body's immune system to attack the cancer. Researchers will see if this approa…

This study is testing if a new drug called RPH-002 is as effective and safe as the standard drug Erbitux for treating advanced head and neck cancer that has spread or returned. About 161 patients will receive either RPH-002 or Erbitux along with standard chemotherapy. The goal is…

This study aimed to test the safety and effectiveness of combining two drugs, TTI-101 and pembrolizumab, for adults with advanced head and neck cancer that had returned or spread. The goal was to see if this combination could help control the cancer better than standard treatment…

This study is testing if adding a new immunotherapy drug called treprizumab to standard chemotherapy before surgery is more effective for treating locally advanced head and neck cancer. It involves 122 patients who are randomly assigned to receive either the new combination or st…

This study is testing a new oral drug, ARRY-614, to see if it can make standard immunotherapy drugs (nivolumab and ipilimumab) work better for people with advanced cancers. The first part checks the safety and best dose. The second part will see how well the combinations work to …

This early-stage study is testing an experimental drug called ABBV-400 in adults with advanced solid tumors that have spread or cannot be removed by surgery. It includes eight specific cancer types, such as liver, pancreatic, and certain breast cancers. The main goals are to chec…

This study is testing whether a newer immunotherapy drug (pembrolizumab) combined with radiation works better than the current standard treatment of chemotherapy plus radiation for people with advanced head and neck cancer. It will involve 126 patients whose cancer is linked to t…

This study is testing a new combination of immune-boosting drugs for people with advanced cancers whose disease has progressed after treatment with standard immunotherapies like pembrolizumab or nivolumab. It aims to see if adding a drug called NAI to other treatments can help sh…

This study is testing whether a new combination of treatments can better shrink tumors before surgery for head and neck cancers caused by HPV. It is for patients with advanced but operable cancer who have not had prior treatment. The goal is to see if adding a vaccine and other i…

This study is testing if adding a pill called lenvatinib to an existing immunotherapy drug (pembrolizumab) works better than the immunotherapy alone to keep cancer from coming back. It's for adults with a specific type of advanced head and neck cancer who have just finished their…

This early-stage study is testing the safety of a new cancer drug called PF-08046032, both by itself and combined with another drug called sasanlimab. It involves a small group of adults with advanced or spreading cancers, including certain lymphomas and solid tumors like lung ca…

This early-stage study is testing a new drug called MCLA-129, which is designed to attack cancer cells by blocking two different growth signals at once. It is for adults with advanced lung, stomach, head/neck, or other solid tumors that have stopped responding to standard treatme…

This study is testing if adding a second immunotherapy drug (domvanalimab) to a standard treatment (zimberelimab plus chemotherapy) works better for people with advanced head and neck cancer that has returned or spread. It will involve about 100 participants who have not yet rece…

This is an early-stage study to find a safe dose of a new immunotherapy drug called HFB200301. It is being tested alone and in combination with an existing drug (tislelizumab) in adults with advanced solid tumors who have already tried other treatments. The main goal is to see ho…

This early-stage study is testing whether adding an experimental drug called berzosertib to standard chemotherapy (cisplatin) and radiation can better treat advanced head and neck cancer. The main goals are to find the safest and most effective dose of this new combination and to…

This study is testing whether adding chemotherapy to a precise, high-dose radiation treatment works better than the radiation treatment alone for patients whose head and neck cancer has spread to only a few other places in the body. The main goal is to see if more patients are al…

This study is testing whether combining two existing drugs, ramucirumab and pembrolizumab, works better than pembrolizumab alone for advanced head and neck cancer that has returned or spread. The first part of the study aims to find a safe dose for the combination. The second par…

This study aims to find out which of two chemotherapy combinations works better for treating advanced head and neck cancer that hasn't been treated before. Researchers will compare two different drug regimens in about 128 patients to see which one better controls the cancer while…

This study is testing whether an immunotherapy drug called tislelizumab, either alone or combined with other experimental drugs, can help control advanced head and neck cancer that has returned or spread. About 160 patients who have not yet received treatment for their advanced c…

This study is testing if adding a common diabetes medication (metformin) to an established cancer immunotherapy (pembrolizumab) can better control advanced head and neck cancer that has spread or returned. It involves about 20 patients who have run out of standard curative option…

This early-stage study is testing the safety and best dose of a new drug called sEphB4-HSA when given alongside standard chemotherapy. It involves about 61 people with specific advanced or spreading cancers, including pancreatic, lung, and head/neck cancers, that have stopped res…

This study is testing if adding a new drug called ipatasertib to a standard immunotherapy (pembrolizumab) works better for controlling advanced head and neck cancer that has returned or spread. It will involve about 52 adults who have not yet received treatment for their advanced…

This study is testing a combination of two immunotherapy drugs given to patients before they have surgery to remove their HPV-negative head and neck cancer. The main goals are to see if the treatment is safe and to learn how it affects immune cells in the tumor. About 27 patients…

This study is testing a new drug combination for people with advanced head and neck cancer that has come back or spread after initial treatment. It aims to see if adding the experimental drug SI-B001 to the chemotherapy drug paclitaxel is safe and can help control the cancer. The…

This is a first-in-human study testing a new type of cancer treatment called P-MUC1C-ALLO1 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see how well the body tolerates this 'off-the-shelf' CAR-T …

This trial is for people with advanced throat cancer. It compares two different combinations of chemotherapy and radiation to see which is better at controlling the cancer while preserving the patient's voice box (larynx). The goal is to avoid total removal of the voice box, whic…

This study is testing a new combination treatment for people with advanced lung cancer, melanoma, kidney cancer, or head and neck cancer that has stopped responding to standard immunotherapy. The treatment involves three parts: a targeted radiation dose to one tumor, injections o…

This study is testing a new drug, FID-007, given alongside an existing cancer drug called cetuximab. It aims to see if this combination can help control advanced head and neck cancer that has come back or spread after prior treatment. Researchers will compare two different dosing…

This early-stage trial is testing the safety and finding the right dose of a two-drug combination (naptumomab estafenatox and durvalumab) for people with advanced or metastatic solid tumors. It will enroll about 120 adults with one of many eligible cancer types, including breast,…

This early-stage study is testing the safety of combining a new cancer vaccine with an existing immunotherapy drug (pembrolizumab) for patients with advanced solid tumors that have spread and stopped responding to standard treatments. The vaccine is designed to train the immune s…

This study is testing an experimental drug called SI-B001 for people with advanced head and neck cancer that has come back or spread after standard treatments stopped working. It aims to see if the drug is safe and can help control the cancer. The trial is open to adults whose ca…

This is an early-stage study testing a new antibody drug called IMT-009 in people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand the side effects, and see if the drug helps shrink tum…

This study is testing a combination of three cancer drugs (cisplatin, nab-paclitaxel, and cetuximab, called CACTUX) for people with incurable head and neck cancer that has spread or returned. The main goal is to see if this combination can help control the cancer for a longer tim…

This study is testing whether adding a vaccine that targets the HPV virus to standard cancer treatments (chemotherapy, radiation, and an immunotherapy drug) can better control a specific type of throat cancer. It is for adults newly diagnosed with intermediate-risk, HPV-16 positi…

This study is testing a new imaging device called MSOT that uses light and sound to create pictures. It aims to see if it can better identify affected lymph nodes in head and neck cancer patients and monitor scarring from radiation treatment. The study will involve 100 patients a…

This study aimed to see if a new lab test could better predict which patients with head and neck cancer would respond to immunotherapy drugs. The test analyzes a piece of the patient's tumor taken before treatment. The trial was withdrawn before any patients were enrolled.

This study is testing whether more frequent symptom check-ins help patients with head and neck cancer during and after radiation treatment. Researchers are comparing a group that fills out detailed symptom surveys twice a week to a group receiving standard weekly check-ins. The g…